Overview

Immunotherapy Drugs Market is estimated to value over USD 270 billion by 2027 end with a CAGR of over 10% during the forecast period 2020 to 2027.

The increasing occurrences of targeted diseases, rising insistence for biosimilars and monoclinal antibodies, rising acceptance of immunotherapy drugs over traditional drugs are some of the key factors responsible for the immunotherapy drugs market growth. Conversely, side-effects of these drugs, issues related to the timeline and complexities in manufacturing and a high rate of attrition in the product development cycle shall impede the proliferation of the market.

Immunotherapy Drugs Market Segmentation:

By Type

Checkpoint Inhibitors
Multiclonal Antibodies
Interleukins
Interferons

By Therapy Area

Cancer
Infectious Diseases
Autoimmune & Inflammatory Diseases

By End User

Clinics
Hospitals
Others

By Region

North America
Europe
Asia Pacific
Latin America
Middle East & Africa

The market is categorised into type, therapy area, end user and region. The type segment is fragmented into check point inhibitors, monoclonal antibodies, interleukins and interferons. The monoclonal antibodies segment held the largest immunotherapy drugs market share owing to fewer side effects and high specificity, rising emphasis on personalised medicines, increased prevalence of targeted diseases and growing initiatives by key market players. The therapy area segment is classified into cancer, infectious diseases and autoimmune & inflammatory diseases. Cancer segment led the market in 2019 and this can be credited to rising incidence of cancer, favourable reimbursement scenarios for oncology. The end user segment is diversified into clinics, hospitals and other end users. The hospital segment is predicted to dominate the market owing to the increased hospital expenditure for immunotherapies.

Regional Analysis:

The North America region is anticipated to dominate the market owing to rising incidences of autoimmune diseases and cancer, rising insistence for safe therapies, growing FDA approvals and favourable reimbursement scenarios.

Competitive Landscape:

Some of the prominent market players are F. Hoffmann-La Roche Ltd., Pfizer Inc., Merck & Co, Novartis International AG, Johnson & Johnson, Sanofi, GlaxoSmithKline Plc, Amgen Inc., Abbvie Inc., Boehringer Ingelheim, AstraZeneca, Immatics Biotechnologies, Biontech SE, Genmab, Gilead Sciences, NBE Therapeutics, Teva Pharmaceuticals, Bayer, and Bristol-Myers Squibb.

FutureWise Key Takeaways:

Growth prospects
SWOT analysis
Key market trends
Key data-points affecting market growth

Objectives of the Study:

To provide with an exhaustive analysis on the global immunotherapy drugs market by type, by therapy area, by end user and by region
To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
To evaluate and forecast micro-markets and the overall market
To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa
To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:

We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
The customization Mobility Care offered are free of charge with purchase of any license of the report
You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com